Ocrevus Reduces MS Relapse Risk, But Linked to More Hospitalizations

Ocrevus Reduces MS Relapse Risk, But Linked to More Hospitalizations

303972

Ocrevus Reduces MS Relapse Risk, But Linked to More Hospitalizations

Ocrevus (ocrelizumab) reduces relapse risk and slows disability progression in multiple sclerosis (MS) but also is associated with higher hospitalization rates in older people with relapsing forms of the disease, a new observational study reports. Hospitalizations — which occurred mainly due to urinary tract infections — were more frequent in adults ages 55 and older than in those below that age, the study found. “Although patients older than 55 were not at higher risk of having…

You must be logged in to read/download the full post.